Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
KYORIN Pharmaceutical Co Ltd (Kyorin), formerly Kyorin Holdings Inc, manufactures and sells prescription medicine, quasi-drugs, and diagnostic drugs. The company leverages its focus on expansion of development pipeline, improved operational performance, and focus on low-cost production to strengthen its position, even as business concentration is major area of concern for the company. Going forward, stringent government regulations, intense competition, and uncertain R&D outcomes could affect its business operations. However, market potential for Acute Myeloid Leukemia, contracts and agreements, and new drug discovery strategies could provide ample growth opportunities to the company.
Strengths
- Focus on Expansion of Development Pipeline
- Proin vel
- Proin vel
- Proin vel
Weaknesses
- Business Concentration
- Proin vel
- Proin vel
- Proin vel
Opportunities
- Market Potential: Acute Myeloid Leukemia (AML)
- Proin vel
- Proin vel
- Proin vel
Threats
- Intense Competition
- Proin vel
- Proin vel
- Proin vel
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer